Moderna IncMRNA
▲ ポジティブ資本関連度
Analysis favors Moderna as better buy, citing proven mRNA platform and expected sales growth to $2.1B in FY2026.
資産への影響 8
Biotech & Genomic Medicine
Moderna Inc
Recursion Pharmaceuticals IncRXRX
▼ ネガティブ資本関連度
Analysis favors Moderna over Recursion, noting Recursion's unproven AI model and anticipated 11% revenue decline in FY2026.
Arbutus Biopharma CorpABUS
言及
GSK plcGSK
言及
Merck & Company IncMRK
言及
Pfizer IncPFE
言及
Artificial Intelligence
Health Care
Sanofi SASAN
言及